| Literature DB >> 34992816 |
Alicia L Eubanks1, David F Grabski1, Jessica Pollack1, Daniel E Levin1, Eugene McGahren1, Linda W Martin1, Jeffrey Gander1.
Abstract
BACKGROUND: A major challenge associated with the Nuss procedure for pectus excavatum repair is postoperative pain control. Early Recovery Program (ERP) protocols for the Nuss procedure are becoming common, but there is a paucity of experience using liposomal bupivacaine (LB), a long-acting local anesthetic, for rib blocks in this setting. We investigated whether a protocol utilizing LB rib blocks decreased opioid use after the Nuss procedure while achieving equivalent pain control.Entities:
Keywords: Early Recovery Program (ERP); Nuss procedure; intercostal block; liposomal bupivacaine (LB); opioid reduction
Year: 2021 PMID: 34992816 PMCID: PMC8662494 DOI: 10.21037/jtd-21-1314
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Perioperative protocols in pre-intervention, transition, and post-intervention cohorts
| Phase of care | Pre-intervention cohort (n=15) | Transition cohort (n=4) | Post-intervention cohort (n=13) |
|---|---|---|---|
| Pre-operative | No pre-medication | Acetaminophen 975 mg | Acetaminophen 975 mg |
| Celecoxib 200 mg | Celecoxib 200 mg | ||
| Gabapentin 300 mg | Gabapentin 300 mg | ||
| Intra-operative | General anesthesia | General anesthesia | General anesthesia |
| Foley catheter placement | Bilateral rib blocks with 0.25% bupivacaine with epinephrine | Bilateral rib blocks with 0.3% LB (2.25 mg/kg) | |
| Rib block with 0.25% Marcaine at conclusion | No Foley catheter placed | No Foley catheter placed | |
| Post-operative | Scheduled acetaminophen | Scheduled acetaminophen | Scheduled acetaminophen 975 mg every 6 hours |
| Scheduled Toradol 30 mg every 6 hours with transition to ibuprofen 600 mg every 4 hours | Scheduled Toradol 30 mg every 6 hours with transition to ibuprofen 600 mg every 4 hours | Scheduled Toradol 30 mg every 6 hours with transition to ibuprofen 600 mg every 4 hours | |
| Opioid PCA (morphine, hydromorphone, or fentanyl) | Scheduled gabapentin 300 mg every 8 hours | Scheduled gabapentin 300 mg every 8 hours | |
| Transition to oral oxycodone | PRN oxycodone 5 mg every 6 hours | As needed (PRN) oxycodone |
LB, liposomal bupivacaine; PCA, patient-controlled analgesia; PRN, as-needed.
Patient demographic and clinical characteristics in pre-intervention, transition, and post-intervention cohorts
| Patient characteristic | Pre-intervention cohort (n=15) | Transition cohort (n=4) | Post-intervention cohort (n=13) | P value |
|---|---|---|---|---|
| Age at operation (years), mean (SD) | 15.4 (2.0) | 15.2 (0.5) | 15.7 (2.1) | 0.35 |
| Weight at operation (kg), mean (SD) | 57.8 (8.8) | 57.5 (5.4) | 66.3 (11.1) | 0.02 |
| Sex, female, n (%) | 5 (33.3) | 1 (25.0) | 0 (0) | |
| ASA Score, median (IQR) | 1 [1, 2] | 1 [1, 1.5] | 2 [1, 2] | 0.276 |
| Haller index, median (IQR) | 5.3 (1.5) | 5.3 (1.5) | 5.4 (1.4) | 0.961 |
| Cardiac dysrhythmia, n (%) | 0 (0) | 0 (0) | 1 (7.6) | |
| Mitral value prolapse, n (%) | 0 (0) | 0 (0) | 1 (7.6) | |
| Second bar placed, n (%) | 4 (26.7) | 1 (25.0) | 2 (15.4) |
ASA Score, American Society of Anesthesiologists Score; IQR, interquartile range; SD, standard deviation.
Figure 1Process-control chart of post-operative morphine equivalents (MME mg/kg). Each point on the X-axis represents an individual patient, and patients are displayed in chronologic order. The blue box represents the transition cohort group (date range, Jan–Dec 2018). UCL, upper control limit; MME, median morphine equivalent.
Pain control data in pre-intervention, roll-out and post-intervention cohorts
| Pain control category | Pre-intervention cohort (n=15) | Transition cohort | Post-intervention cohort (n=13) | P value |
|---|---|---|---|---|
| Intra-operative median morphine equivalents (mg/kg) median (IQR) | 1.4 (0.7, 2.5) | 1.1 (0.1, 2.3) | 0.4 (0.1, 1.4) | 0.022 |
| Post-operative median morphine equivalents (mg/kg) median (IQR) | 8.2 (6.1, 9.4) | 1.2 (0.6, 3.5) | 0.8 (0.5, 1.3) | <0.0001 |
| Intra-operative liposomal bupivacaine (mg), mean (SD) | 0 (0) | 0 (0) | 165.2 (52.0) | |
| Post-operative gabapentin (g), mean (SD) | 0 (0) | 3.38 (1.79) | 3.0 (1.3) | |
| Post-operative PO acetaminophen (g), median (IQR) | 7.3 (4.5, 9.7) | 9.7 (9.7, 11.9) | 10.7 (7.8, 12.2) | 0.032 |
| Post-operative ibuprofen (g), median (IQR) | 2 (0.4, 4.8) | 2.2 (1.8, 2.6) | 1.8 (1.2, 3.0) | 0.488 |
| Post-operative IV Toradol (mg), median (IQR) | 198.5 (135.0, 330.0) | 157.5 (119.7, 246.0) | 230.3 (195.0, 240.0) | 0.818 |
| Pain score | ||||
| 0–24 hours (maximum), median [IQR] | 8 [7, 10] | 5 [3, 8.5] | 8.5 [7, 10] | 0.535 |
| 24–48 hours (maximum), median [IQR] | 7 [5, 8] | 6 [4.5, 7] | 6.5 [6, 8] | 0.689 |
| 48–72 hours (maximum), median [IQR] | 6 [5, 8] | 7 [5.5, 8.5] | 6 [4.5, 8] | 0.675 |
IQR, interquartile range; SD, standard deviation; PO, by mouth.
Figure 2Patient-reported maximum pain scores in the first 72 hours after Nuss procedure
Operative time and post-operative length of stay in pre-intervention, roll-out and post-intervention cohorts
| Clinical parameter | Pre-intervention cohort (n=15) | Transition cohort | Post-intervention cohort (n=13) | P value |
|---|---|---|---|---|
| Post-operative LOS (days) median [IQR] | 4 [3, 5] | 3 [3, 4.5] | 3 [2.5, 3] | 0.002 |
| Length of case (hours intubated intra-operatively) mean (SD) | 3.5 (0.6) | 3.5 (0.9) | 3.5 (0.4) | 0.9 |
LOS, length of stay, n, number of patients; IQR, interquartile range; SD, standard deviation.